Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients.

Cancer chemotherapy and pharmacology - 1 Mar 2010

Fidlerova Julie, Kleiblova Petra, Bilek Matej, Kormunda Stanislav, Formankova Zuzana, Novotny Jan, Kleibl Zdenek

Abstract excerpt

PURPOSE: Decreased 5-fluorouracil catabolism has been considered a major factor contributing to fluoropyrimidine (FP)-related toxicity. Alterations in the dihydropyrimidine dehydrogenase gene coding for the first and rate-limiting enzyme of FP catabolic pathway could explain toxicity in only a li...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amidohydrolases
Share to Antimetabolites, Antineoplastic
Share to Chi-Square Distribution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug-Related Side Effects and Adverse Reactions

Share to Fluorouracil

Share to Haplotypes

Share to Neoplasms

Share to Odds Ratio

Source

Identifiers

PMID: 19649633
DOI: 10.1007/s00280-009-1071-0

Genes

DPYS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19649633-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients.PMID 19649633Read ↗

Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.Semantic proximity Read ↗

Common dihydropyrimidinase ( DPYS ) genetic variations do not predict fluoropyrimidine-related chemotherapy toxicity in a Canadian cohort.Semantic proximity Read ↗

Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.Semantic proximity Read ↗

Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping AssaysSemantic proximity Read ↗

DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand?Semantic proximity Read ↗

Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.Semantic proximity Read ↗

Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.Semantic proximity Read ↗

DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol.Semantic proximity Read ↗

Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase.Semantic proximity Read ↗

DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol.Semantic proximity Read ↗

Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.